Plus Therapeutics flags availability of CNS cancers guidelines update release

PLUS THERAPEUTICS INC

PLUS THERAPEUTICS INC

PSTV

0.00
  • Plus Therapeutics posted a press release highlighting updated NCCN CNS cancer guidelines that reaffirm routine CSF testing for leptomeningeal metastases monitoring.
  • The release points to CNSide data showing more than double the tumor-detection sensitivity versus conventional CSF cytology in matched samples.
  • Plus cited contracted coverage of about 126 million lives, targeting 150 million lives and 1,250 CNSide tests in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140730PRIMZONEFULLFEED9761129) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.